Please ensure Javascript is enabled for purposes of website accessibility

Why Abbott Shares Rose 16.7% in April

By Adria Cimino - May 4, 2020 at 9:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The launch of a third coronavirus test and optimism about a fourth boosted the stock.

What happened

Shares of Abbott Laboratories (ABT -1.09%) rose 16.7% in April, according to data provided by S&P Global Market Intelligence, as the company launched a third coronavirus test and announced work on a fourth.

A scientist with gloved hands holds a coronavirus blood sample.

Images source: Getty Images.

The company launched its first two coronavirus tests in late March and followed up with another test last month. The first two are molecular coronavirus detection tests, with one being the world's fastest. This portable test can be used in point-of-care situations and produces positive results in as little as five minutes and negative results in 13 minutes. The latest test is an antibody blood test that determines if a person has been previously infected with COVID-19, the illness caused by the coronavirus.

Abbott said during its latest earnings call that it now is working on a lateral flow serology test that would make mass testing across the entire population possible.

So what

As COVID-19 cases top 3.4 million worldwide, testing is greatly needed. Local and national governments have struggled to obtain tests, as well as determine a way to test everyone. The development of a lateral flow serology test, a simple method that is easy to roll out on a large scale, may be a solution to the problem.

Abbott's launch of the COVID-19 tests was too recent to contribute to first-quarter earnings, but the company said in its earnings call that these tests will be more significant in the next report.

Now what

Abbott saw a decline in some diagnostic tests in the first quarter as nonessential procedures were postponed due to the coronavirus outbreak. As a result, revenue in core laboratory diagnostics fell 6.8%. Still, other tests compensated, and total diagnostics revenue only slipped 0.8%. Investors will be watching the next earnings report to see how the coronavirus tests are contributing to diagnostics revenue.

The focus also will be on the development of the lateral flow serology test as screening of the general population represents a big opportunity. CEO Robert B. Ford didn't offer an exact development time frame for this test, but in the earnings call, he said, "We're almost there."

And finally, investors should look to see if Abbott can meet shipping goals for its tests. Abbott said that for the latest version (the antibody blood test), it aims to ship 20 million per month in the U.S. as of June.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$110.81 (-1.09%) $-1.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.